DK0800536T3 - Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser - Google Patents

Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser

Info

Publication number: DK0800536T3
Authority: DK; Denmark
Prior art keywords: treatment; pct; recombinant; mediated disorders; antagonists useful
Prior art date: 1994-12-23

Application number

DK95944692T

Other languages

English (en)

Inventor

Irwin M Chaiken

Mitchell Stuart Gross

Stephen Dudley Holmes

Robert S Ames

Edward Robert Appelbaum

Richard M Cook

Lynette Jane Mcmillan

Timothy Wayne Theisen

Original Assignee

Smithkline Beecham Corp

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-23

Filing date

1995-12-22

Publication date

2007-04-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27408594&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0800536(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-06 Priority claimed from US08/470,110 external-priority patent/US5693323A/en

1995-12-22 Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp

2007-04-02 Application granted granted Critical

2007-04-02 Publication of DK0800536T3 publication Critical patent/DK0800536T3/da

Links

108010002616 Interleukin-5 Proteins 0.000 title abstract 3
102000000743 Interleukin-5 Human genes 0.000 title 2
239000005557 antagonist Substances 0.000 title 1
230000001404 mediated effect Effects 0.000 title 1
230000003472 neutralizing effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Zoology (AREA)
Hematology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Heart & Thoracic Surgery (AREA)
Otolaryngology (AREA)
Cardiology (AREA)
Dermatology (AREA)

DK95944692T 1994-12-23 1995-12-22 Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser DK0800536T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US36313194A	1994-12-23	1994-12-23
US08/470,110 US5693323A (en)	1994-12-23	1995-06-06	Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/467,420 US5683892A (en)	1994-12-23	1995-06-06	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
PCT/US1995/017082 WO1996021000A2 (en)	1994-12-23	1995-12-22	Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders

Publications (1)

Publication Number	Publication Date
DK0800536T3 true DK0800536T3 (da)	2007-04-02

Family

ID=27408594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95944692T DK0800536T3 (da)	1994-12-23	1995-12-22	Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser

Country Status (22)

Country	Link
US (1)	US6129913A (da)
EP (1)	EP0800536B1 (da)
JP (2)	JP2001523083A (da)
CN (1)	CN100391977C (da)
AT (1)	ATE346867T1 (da)
AU (1)	AU708951B2 (da)
BR (1)	BR9510499B1 (da)
CA (1)	CA2208503C (da)
CZ (1)	CZ297045B6 (da)
DE (1)	DE69535319T2 (da)
DK (1)	DK0800536T3 (da)
ES (1)	ES2277336T3 (da)
FI (1)	FI119374B (da)
HK (1)	HK1003651A1 (da)
HU (1)	HU222992B1 (da)
LU (1)	LU92912I2 (da)
MX (1)	MX9704779A (da)
NL (1)	NL300787I1 (da)
NO (2)	NO324181B1 (da)
NZ (1)	NZ301916A (da)
PL (1)	PL194312B1 (da)
WO (1)	WO1996021000A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5693323A (en) *	1994-12-23	1997-12-02	Smithkline Beecham Corporation	Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) *	1994-12-23	1998-07-21	Smithkline Beecham Corporation	Method for treatment and diagnosis of IL-5 mediated disorders
EP2275540B1 (en)	1999-04-09	2016-03-23	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) *	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2479927C (en) *	2002-03-29	2013-03-12	Schering Corporation	Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
US7691568B2 (en)	2002-04-09	2010-04-06	Kyowa Hakko Kirin Co., Ltd	Antibody composition-containing medicament
US20070219117A1 (en) *	2003-10-27	2007-09-20	Medvet Science Pty Ltd	Bidentate motif and methods of use
EP1810690B1 (en) *	2004-10-28	2012-01-18	Kyowa Hakko Kirin Co., Ltd.	Anti-IL-5 receptor antibody for use in treating endometriosis.
JP2010526087A (ja)	2007-04-30	2010-07-29	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	抗ｉｌ−５抗体を投与するための方法
JP4335286B2 (ja)	2008-02-08	2009-09-30	ファナック株式会社	部品保護機能を備えたロボット制御装置及びロボット制御方法
ES2441945T3 (es)	2008-03-28	2014-02-07	Glaxosmithkline Llc	Métodos de tratamiento
EA023700B1 (ru) *	2010-01-28	2016-07-29	Глаксо Груп Лимитед	Cd127-связывающие белки
CA2824279A1 (en)	2010-12-22	2012-06-28	Cephalon Australia Pty Ltd	Modified antibody with improved half-life
MA42692A (fr)	2015-08-24	2018-07-04	Glaxosmithkline Ip No 2 Ltd	Compositions biopharmaceutiques
CN109195990A (zh) *	2016-03-30	2019-01-11	Musc研究发展基金会	通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
RU2758008C2 (ru)	2016-12-23	2021-10-25	Сефалон, Инк.	Анти-il-5 антитела
EA201992802A1 (ru) *	2017-05-26	2020-07-10	Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	Биофармацевтические композиции и связанные с ними способы
CN111065651B (zh) *	2017-09-29	2023-07-14	江苏恒瑞医药股份有限公司	Il-5抗体、其抗原结合片段及医药用途
CN109942706A (zh) *	2017-12-21	2019-06-28	三生国健药业（上海）股份有限公司	结合人il-5的单克隆抗体、其制备方法和用途
US20220010008A1 (en) *	2018-12-12	2022-01-13	Shanghai Pharmaexplorer Co., Ltd.	Anti-human interleukin 5(il-5) monoclonal antibody and use thereof
WO2020200099A1 (zh) *	2019-03-29	2020-10-08	江苏恒瑞医药股份有限公司	包含抗il-5抗体的药物组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8800397D0 (en) *	1988-01-08	1988-02-10	Sandoz Ltd	Improvements in/relating to organic compounds
WO1990004979A2 (en) *	1988-11-03	1990-05-17	Schering Corporation	Method of preventing or reducing eosinophilia
US5096704A (en) *	1988-11-03	1992-03-17	Schering Corporation	Method of treating eosinophilia
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ZA929328B (en) *	1991-12-02	1993-07-20	Fluor Corp	Apparatus and method for economic use of excess compressed air when firing low caloric-value gas in a combustion gas turbine.
KR0150060B1 (ko) *	1992-02-06	1998-08-17	에릭 에스. 딕커	사람 인터루킨-5에 대한 인간화 모노클로날 항체의 고안, 클로닝 및 발현
JPH06141885A (ja) *	1992-11-05	1994-05-24	Chemo Sero Therapeut Res Inst	モノクローナル抗体
AU1289795A (en) *	1993-11-19	1995-06-06	Baylor College Of Medicine	Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) *	1994-06-17	1994-08-10	Celltech Ltd	Interleukin-5 specific recombiant antibodies
US5693323A (en) *	1994-12-23	1997-12-02	Smithkline Beecham Corporation	Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) *	1994-12-23	1998-07-21	Smithkline Beecham Corporation	Method for treatment and diagnosis of IL-5 mediated disorders
WO2001012646A1 (en) *	1999-08-19	2001-02-22	Smithkline Beecham Corporation	Sialoadhesin factor-1 agonist and antagonist antibodies

1995
- 1995-12-22 DE DE69535319T patent/DE69535319T2/de not_active Expired - Lifetime
- 1995-12-22 AU AU47450/96A patent/AU708951B2/en not_active Expired
- 1995-12-22 US US08/637,647 patent/US6129913A/en not_active Expired - Lifetime
- 1995-12-22 BR BRPI9510499-2A patent/BR9510499B1/pt active IP Right Grant
- 1995-12-22 MX MX9704779A patent/MX9704779A/es unknown
- 1995-12-22 DK DK95944692T patent/DK0800536T3/da active
- 1995-12-22 AT AT95944692T patent/ATE346867T1/de active
- 1995-12-22 WO PCT/US1995/017082 patent/WO1996021000A2/en active IP Right Grant
- 1995-12-22 CZ CZ0196397A patent/CZ297045B6/cs not_active IP Right Cessation
- 1995-12-22 NZ NZ301916A patent/NZ301916A/xx not_active IP Right Cessation
- 1995-12-22 CN CNB951977016A patent/CN100391977C/zh not_active Expired - Lifetime
- 1995-12-22 HU HU9901120A patent/HU222992B1/hu active Protection Beyond IP Right Term
- 1995-12-22 EP EP95944692A patent/EP0800536B1/en not_active Expired - Lifetime
- 1995-12-22 ES ES95944692T patent/ES2277336T3/es not_active Expired - Lifetime
- 1995-12-22 PL PL95321088A patent/PL194312B1/pl unknown
- 1995-12-22 CA CA002208503A patent/CA2208503C/en not_active Expired - Lifetime
- 1995-12-22 JP JP52118996A patent/JP2001523083A/ja not_active Withdrawn
1997
- 1997-06-20 NO NO19972913A patent/NO324181B1/no not_active IP Right Cessation
- 1997-06-23 FI FI972703A patent/FI119374B/fi not_active IP Right Cessation
1998
- 1998-04-09 HK HK98103015A patent/HK1003651A1/xx not_active IP Right Cessation
2007
- 2007-10-16 JP JP2007269236A patent/JP2008029355A/ja not_active Withdrawn
2015
- 2015-12-16 LU LU92912C patent/LU92912I2/xx unknown
- 2015-12-18 NO NO2015027C patent/NO2015027I2/no unknown
- 2015-12-18 NL NL300787C patent/NL300787I1/nl unknown

Also Published As

Publication number	Publication date
CN100391977C (zh)	2008-06-04
ES2277336T3 (es)	2007-07-01
US6129913A (en)	2000-10-10
AU4745096A (en)	1996-07-24
AU708951B2 (en)	1999-08-19
CZ196397A3 (en)	1997-10-15
BR9510499B1 (pt)	2009-05-05
WO1996021000A2 (en)	1996-07-11
BR9510499A (pt)	1999-03-30
FI972703A (fi)	1997-08-22
EP0800536B1 (en)	2006-11-29
FI119374B (fi)	2008-10-31
NO324181B1 (no)	2007-09-03
DE69535319T2 (de)	2007-07-19
NZ301916A (en)	1999-05-28
NL300787I2 (da)	2016-04-05
NL300787I1 (da)	2016-04-05
WO1996021000A3 (en)	1996-09-06
EP0800536A2 (en)	1997-10-15
JP2008029355A (ja)	2008-02-14
EP0800536A4 (en)	2004-12-01
HU222992B1 (hu)	2004-01-28
MX9704779A (es)	1997-09-30
CA2208503C (en)	2009-12-01
NO972913L (no)	1997-08-19
HK1003651A1 (en)	1998-11-06
CA2208503A1 (en)	1996-07-11
HUT78055A (hu)	1999-07-28
CZ297045B6 (cs)	2006-08-16
LU92912I2 (fr)	2016-02-16
NO2015027I2 (no)	2016-01-04
ATE346867T1 (de)	2006-12-15
CN1175263A (zh)	1998-03-04
DE69535319D1 (de)	2007-01-11
NO972913D0 (no)	1997-06-20
FI972703A0 (fi)	1997-06-23
PL321088A1 (en)	1997-11-24
NO2015027I1 (no)	2015-12-18
PL194312B1 (pl)	2007-05-31
JP2001523083A (ja)	2001-11-20

Publication	Publication Date	Title
DK0800536T3 (da)	2007-04-02	Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser
BR0008688A (pt)	2002-01-08	Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
SE9604793D0 (sv)	1996-12-20	New polymorphs
ES2108120T3 (es)	1997-12-16	Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
DK0771197T3 (da)	2003-06-23	Anvendelse af heterocykliske forbindelser som dopamin-D3-ligander
DK0726765T3 (da)	2001-10-15	Apparat og fremgangsmåde til fremstilling af faste former med styret frigivelse af den aktive bestanddel
LU91271I2 (fr)	2006-10-02	Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
YU48528B (sh)	1998-11-05	Analozi 5-(1-hidroksi-2-piperidinopropil)-2-(1h,3h)-indolona
FI971967A0 (fi)	1997-05-07	Dioksomorfoliinien käyttö sisäloisten torjuntaan, uusia dioksomorfiineja ja menetelmä niiden valmistamiseksi
YU7797A (sh)	2000-10-30	Kombinovana terapija za osteoporozu
BR9910180A (pt)	2001-01-09	Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
DK0473671T3 (da)	1994-09-19	Anvendelse af sigma-receptorligander til fremstilling af et anxiolytisk middel
UA48940C2 (uk)	2002-09-16	Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень
DK0712311T3 (da)	1999-06-21	Antiglucocorticoidsteroider til behandling af angstlidelser
DK0989973T3 (da)	2005-10-17	Chalconer med antiproliferativ aktivitet
FI973221A0 (fi)	1997-08-04	1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
ATE78162T1 (de)	1992-08-15	5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.
ES2091039T3 (es)	1996-10-16	Nuevos bis-fenil-hexenos.
DK0817863T3 (da)	1999-12-20	Fremgangsmåde til fremstiling af spirolaxin-methylether